Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 179

1.

Inhibition of the isoprenoid biosynthesis pathway; detection of intermediates by UPLC-MS/MS.

Henneman L, van Cruchten AG, Kulik W, Waterham HR.

Biochim Biophys Acta. 2011 Apr;1811(4):227-33. doi: 10.1016/j.bbalip.2011.01.002. Epub 2011 Jan 13.

PMID:
21237288
2.

Effects of farnesyl pyrophosphate accumulation on calvarial osteoblast differentiation.

Weivoda MM, Hohl RJ.

Endocrinology. 2011 Aug;152(8):3113-22. doi: 10.1210/en.2011-0016. Epub 2011 May 17.

PMID:
21586555
3.

A novel bisphosphonate inhibitor of squalene synthase combined with a statin or a nitrogenous bisphosphonate in vitro.

Wasko BM, Smits JP, Shull LW, Wiemer DF, Hohl RJ.

J Lipid Res. 2011 Nov;52(11):1957-64. doi: 10.1194/jlr.M016089. Epub 2011 Sep 8.

4.

The intermediate enzymes of isoprenoid metabolism as anticancer targets.

Wiemer AJ, Hohl RJ, Wiemer DF.

Anticancer Agents Med Chem. 2009 Jun;9(5):526-42. Review.

PMID:
19519294
5.

Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.

Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G.

Arch Biochem Biophys. 2000 Jan 1;373(1):231-41.

PMID:
10620343
6.

[Pharmacological control of biosynthesis pathway of mevalonate: effect on the proliferation of arterial smooth muscle cells].

Corsini A, Arnaboldi L, Quarato P, Ferri N, Granata A, Fumagalli R, Paoletti R.

C R Seances Soc Biol Fil. 1997;191(2):169-94. French.

PMID:
9255346
7.

Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation.

Brusselmans K, Timmermans L, Van de Sande T, Van Veldhoven PP, Guan G, Shechter I, Claessens F, Verhoeven G, Swinnen JV.

J Biol Chem. 2007 Jun 29;282(26):18777-85. Epub 2007 May 5.

8.

Manipulation of isoprenoid biosynthesis as a possible therapeutic option in mevalonate kinase deficiency.

Schneiders MS, Houten SM, Turkenburg M, Wanders RJ, Waterham HR.

Arthritis Rheum. 2006 Jul;54(7):2306-13.

10.

Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Yeganeh B, Wiechec E, Ande SR, Sharma P, Moghadam AR, Post M, Freed DH, Hashemi M, Shojaei S, Zeki AA, Ghavami S.

Pharmacol Ther. 2014 Jul;143(1):87-110. doi: 10.1016/j.pharmthera.2014.02.007. Epub 2014 Feb 26. Review.

11.

Massive production of farnesol-derived dicarboxylic acids in mice treated with the squalene synthase inhibitor zaragozic acid A.

Vaidya S, Bostedor R, Kurtz MM, Bergstrom JD, Bansal VS.

Arch Biochem Biophys. 1998 Jul 1;355(1):84-92.

PMID:
9647670
13.

Bisphosphonates induce autophagy by depleting geranylgeranyl diphosphate.

Wasko BM, Dudakovic A, Hohl RJ.

J Pharmacol Exp Ther. 2011 May;337(2):540-6. doi: 10.1124/jpet.110.175521. Epub 2011 Feb 18.

15.

Targeting isoprenoid biosynthesis for drug discovery: bench to bedside.

Oldfield E.

Acc Chem Res. 2010 Sep 21;43(9):1216-26. doi: 10.1021/ar100026v.

16.

Statins and the squalene synthase inhibitor zaragozic acid stimulate the non-amyloidogenic pathway of amyloid-beta protein precursor processing by suppression of cholesterol synthesis.

Kojro E, F├╝ger P, Prinzen C, Kanarek AM, Rat D, Endres K, Fahrenholz F, Postina R.

J Alzheimers Dis. 2010;20(4):1215-31. doi: 10.3233/JAD-2010-091621.

PMID:
20413873
17.

Squalene synthase inhibition alters metabolism of nonsterols in rat liver.

Keller RK.

Biochim Biophys Acta. 1996 Oct 18;1303(3):169-79.

PMID:
8908150
19.
20.

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

Thompson K, Rogers MJ.

J Bone Miner Res. 2004 Feb;19(2):278-88. Epub 2003 Dec 16.

Supplemental Content

Support Center